Who are Alprazolam + Aerobic exercise's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alprazolam-aerobic-exercise.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Alprazolam + Aerobic exercise — Competitive Intelligence Brief

Alprazolam + Aerobic exercise (Alprazolam + Aerobic exercise) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine (alprazolam component); behavioral intervention (aerobic exercise component). Area: Psychiatry / Mental Health.

marketed Benzodiazepine (alprazolam component); behavioral intervention (aerobic exercise component) GABA-A receptor (alprazolam); multiple neurobiological targets including monoamine systems and BDNF pathways (exercise) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Alprazolam + Aerobic exercise (Alprazolam + Aerobic exercise) — University of Buenos Aires. Alprazolam reduces anxiety and panic by enhancing GABAergic inhibition in the central nervous system, while aerobic exercise improves mood and anxiety symptoms through neurobiological adaptations including increased endorphin release and improved cardiovascular function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alprazolam + Aerobic exercise TARGET	Alprazolam + Aerobic exercise	University of Buenos Aires	marketed	Benzodiazepine (alprazolam component); behavioral intervention (aerobic exercise component)	GABA-A receptor (alprazolam); multiple neurobiological targets including monoamine systems and BDNF pathways (exercise)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzodiazepine (alprazolam component); behavioral intervention (aerobic exercise component) class)

University of Buenos Aires · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alprazolam + Aerobic exercise — Competitive Intelligence Brief. https://druglandscape.com/ci/alprazolam-aerobic-exercise. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab